BPC-157 FDA Approval History: Current Regulatory Status and What It Means

BPC-157 Has Never Received FDA Approval

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a sequence found in human gastric juice. Despite widespread online claims about its regenerative properties, the FDA has never approved BPC-157 for any therapeutic indication. No pharmaceutical company has submitted or received a New Drug Application for this compound.

The peptide first appeared in scientific literature through the work of Predrag Sikiric and colleagues at the University of Zagreb, who published preclinical studies beginning in the 1990s. A 2018 review by Sikiric et al. in the Journal of Physiology and Pharmacology summarized decades of animal data showing effects on gastrointestinal healing, tendon repair, and vascular function in rodent models 1. That body of work, while extensive in scope, remains confined to animal experiments. The FDA requires Phase I, II, and III human trials demonstrating both safety and efficacy before granting approval, a threshold BPC-157 has not approached.

A search of the FDA's Drugs@FDA database returns zero results for BPC-157, body protection compound, or the peptide's amino acid sequence. The compound also does not appear in the FDA's Orange Book of approved drug products with therapeutic equivalence evaluations.

The FDA's Category 2 Designation Changed Everything

In December 2023, the FDA placed BPC-157 on its Category 2 list under the agency's evaluation of bulk drug substances used in compounding. This designation means the FDA identified significant safety concerns that, in the agency's assessment, make BPC-157 unsuitable for pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act 2.

The Category 2 classification was not a sudden decision. The FDA had been evaluating peptides used by compounding pharmacies for several years prior. The agency's concerns centered on three issues: lack of adequate safety data in humans, absence of a USP monograph establishing identity and purity standards, and reports of adverse events associated with compounded peptide products.

Before this designation, BPC-157 was widely available through 503A compounding pharmacies that prepared patient-specific formulations under individual prescriptions. Some clinicians, particularly in sports medicine, anti-aging practices, and integrative medicine, prescribed compounded BPC-157 for off-label uses including tendon injuries, gut healing, and post-surgical recovery. The Category 2 listing effectively ended legal compounding of BPC-157 in the United States.

"Compounded drugs are not FDA-approved. This means they have not undergone FDA premarket review for safety, effectiveness, or quality," the FDA stated in its compounding policy page 3.

Why No FDA-Approved Label Exists for BPC-157

An FDA-approved drug label (also called prescribing information or package insert) is generated only after a drug successfully completes the NDA process. Since BPC-157 has never entered this process, no official label exists. There is no approved dosing, no black box warning, no listed contraindications, and no pharmacokinetic data recognized by any regulatory authority.

The doses cited in online forums and clinic websites (typically 200 to 800 mcg per day via subcutaneous injection or oral capsule) originate from extrapolations of animal study doses, not from any human dose-finding trial. Without Phase I pharmacokinetic studies, the absorption, distribution, metabolism, and excretion profile of BPC-157 in humans remains unknown. The FDA's guidance on investigational new drugs requires this data before a compound can progress to efficacy trials 4.

This absence of a label also means there is no FDA-reviewed safety information. Patients using BPC-157 have no regulatory reference document describing drug interactions, contraindications in pregnancy, hepatic or renal dosing adjustments, or long-term toxicity data. Every prescribing decision was made based on clinician judgment and preclinical literature alone.

The Preclinical Evidence: Extensive but Insufficient for Approval

Sikiric and colleagues have published over 100 papers on BPC-157 since the early 1990s. The 2018 review in the Journal of Physiology and Pharmacology detailed the peptide's effects across multiple organ systems in animal models, including acceleration of tendon-to-bone healing, gastric ulcer repair, and modulation of the nitric oxide system 1. In rat models, BPC-157 at doses of 10 mcg/kg and 10 ng/kg demonstrated promotion of angiogenesis and reduction of inflammatory markers.

A separate 2021 analysis published in Life Sciences examined BPC-157's effects on ligament healing in rats and reported statistically significant improvements in tensile strength at 14 days compared to controls 5. These findings, while consistent across multiple rodent studies, share a common limitation. The vast majority originated from a single research group, and independent replication by other laboratories has been limited.

The gap between animal evidence and human approval is wide. The FDA reports that approximately 90% of drugs that enter Phase I human trials fail to achieve approval 6. For a compound like BPC-157, which has not even entered Phase I, the distance to market authorization is substantial. Promising rodent data is a starting point, not a finish line.

FDA Enforcement Actions Against Peptide Products

The FDA's regulatory scrutiny of BPC-157 sits within a broader enforcement campaign targeting compounded peptides. In 2023 and 2024, the agency issued multiple warning letters to compounding pharmacies producing peptide products without adequate quality controls 7.

Specific FDA concerns about compounded peptides have included sterility failures in injectable formulations, inaccurate potency (some tested products contained significantly more or less active ingredient than labeled), and marketing claims that compounded peptides could treat, cure, or prevent diseases. The agency has been particularly focused on peptides sold through telehealth platforms and online clinics that may not maintain adequate physician-patient relationships.

In a 2024 statement, the FDA noted that "patients may be at risk when they use compounded drugs that have not been manufactured under the quality standards that apply to FDA-approved drugs" 7. This language applies directly to BPC-157, which was compounded without FDA-approved manufacturing specifications, validated stability data, or standardized potency testing.

BPC-157 Safety Profile: What We Know and What We Don't

The safety data for BPC-157 in humans is almost nonexistent in peer-reviewed literature. Animal toxicology studies conducted by Sikiric et al. reported no lethal dose identified in rodents (the LD1 was not reached even at very high doses), and no observed organ toxicity at therapeutic doses over study durations of several weeks 1.

These animal safety findings, while reassuring in a preclinical context, do not substitute for human safety data. The FDA Adverse Event Reporting System (FAERS) contains a limited number of reports related to compounded BPC-157, but because the compound was never approved, systematic pharmacovigilance data does not exist 8.

Known theoretical risks include effects on angiogenesis (new blood vessel formation), which could be problematic in patients with active cancers or a history of malignancy. BPC-157 has demonstrated pro-angiogenic activity in multiple animal models 1. A peptide that promotes blood vessel growth could theoretically support tumor vascularization, although this risk has not been studied in oncology populations.

Other concerns include potential effects on blood pressure regulation (BPC-157 interacts with the nitric oxide pathway), unknown interactions with anticoagulant medications, and the complete absence of reproductive toxicology data. Pregnant or breastfeeding patients have zero safety data to reference.

International Regulatory Status

BPC-157's regulatory challenges extend beyond the United States. The European Medicines Agency (EMA) has not evaluated or authorized BPC-157 through its centralized or decentralized procedures. No Marketing Authorization Application (MAA) has been submitted for BPC-157 in any EU member state 9.

In Australia, the Therapeutic Goods Administration (TGA) classifies BPC-157 as a Schedule 4 (prescription-only) substance that is not included in the Australian Register of Therapeutic Goods. Health Canada has not approved BPC-157. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited list under the category of peptide hormones and growth factors, effective January 2022 10.

This global regulatory consensus is notable. Not a single national drug regulatory authority has approved BPC-157 for human use. The compound exists in a regulatory gap: too well-known to ignore, too poorly studied in humans to approve.

What Would It Take for BPC-157 to Gain FDA Approval?

The pathway to FDA approval for BPC-157 would follow the standard New Drug Application process, and the steps required are substantial. A sponsor (pharmaceutical company or academic institution) would need to file an Investigational New Drug (IND) application including chemistry, manufacturing, and controls (CMC) data, preclinical pharmacology and toxicology packages, and a Phase I protocol 4.

Phase I trials would establish human pharmacokinetics, maximum tolerated dose, and acute safety in a small cohort (typically 20 to 80 healthy volunteers). Phase II would test efficacy signals in patients with the target condition across several hundred participants. Phase III would require large, randomized, placebo-controlled trials, often involving 1,000 or more patients, demonstrating statistically significant and clinically meaningful benefit.

The estimated cost for bringing a new drug through this full process ranges from $1.3 billion to $2.6 billion, according to a 2020 analysis published in JAMA by Wouters et al. 11. BPC-157 presents an additional challenge: as a naturally occurring peptide fragment, it may face difficulties obtaining patent protection strong enough to justify that investment. Without patent exclusivity, a sponsor has limited ability to recoup development costs, which partly explains why no pharmaceutical company has pursued formal development.

The Current Situation for Patients and Clinicians

As of mid-2026, BPC-157 remains unavailable through legal compounding channels in the United States. Patients who previously obtained BPC-157 through compounding pharmacies have lost access unless they source it through unregulated channels, which the FDA explicitly warns against.

Clinicians who previously prescribed compounded BPC-157 face a straightforward regulatory reality: prescribing an unapproved substance from unregulated sources exposes both the prescriber and the patient to legal and safety risks. The American Medical Association's principles on compounding support the use of compounded medications only when a commercially available FDA-approved product does not meet the patient's needs and the compounding is performed by a licensed pharmacy under appropriate quality standards 12.

Products labeled as "BPC-157" sold through online retailers, international suppliers, or "research chemical" vendors are not subject to FDA manufacturing oversight. Independent analyses have found that peptide products from unregulated sources frequently contain incorrect doses, contaminants, or entirely different compounds than what is listed on the label 7. Patients considering these sources should discuss the risks with their healthcare provider.